Amantadine Safety for EPS in Geriatric Patients

Critical Safety Concerns in Geriatric Patients

The daily dose for persons aged ≥65 years must not exceed 100 mg for either prophylaxis or treatment, as recommended by the Centers for Disease Control and Prevention, due to dose-dependent toxicity 1, 2
Elderly women are at higher risk than elderly men for side effects at 100 mg/day due to smaller average body size, according to the Centers for Disease Control and Prevention 3
Some elderly persons require further dose reduction below 100 mg/day to minimize serious CNS toxicity, as suggested by the Centers for Disease Control and Prevention 1, 2

Renal Function Considerations

Amantadine is excreted unchanged in the urine; renal clearance is substantially reduced in patients with renal insufficiency, as reported by the Centers for Disease Control and Prevention 1
Renal function declines with increasing age, necessitating dose reduction in all elderly patients, according to the Centers for Disease Control and Prevention 1, 2
Dosage reduction is required for creatinine clearance ≤50 mL/min/1.73m² to prevent accumulation of the drug, as recommended by the Centers for Disease Control and Prevention 1, 2

Monitoring and Management Algorithm

Verify renal function before initiating amantadine in any elderly patient, as recommended by the Centers for Disease Control and Prevention 1
Start at 100 mg/day maximum (not the standard 200 mg/day dose) and consider further reduction below 100 mg/day for elderly women, those with any degree of renal impairment, or those with seizure/psychiatric history, according to the Centers for Disease Control and Prevention 1, 3, 2
Monitor closely for CNS toxicity (confusion, hallucinations, agitation) especially in the first week, as suggested by the Centers for Disease Control and Prevention 1
Reduce dose or discontinue immediately if serious side effects emerge, as recommended by the Centers for Disease Control and Prevention 1

Specific Safety Precautions

Patients with seizure disorders require close observation for increased seizure activity, as reported by the Centers for Disease Control and Prevention 1

Side Effects of Amantadine

Introduction to Side Effects

Amantadine causes CNS side effects in approximately 13% of patients at standard dosing (200 mg/day), which is significantly higher than placebo (4%) and includes nervousness, anxiety, insomnia, difficulty concentrating, and lightheadedness 4, 5, 6

Common and Less Common Side Effects

The most frequently reported adverse reactions at recommended doses include nausea 6
Dizziness (lightheadedness) is a common side effect 5
Insomnia is a common side effect 6
Constipation is a less common side effect 6

Gastrointestinal and Serious Side Effects

Gastrointestinal side effects (nausea and anorexia) occur in approximately 1-3% of persons taking amantadine, which is comparable to placebo rates of 1% 4, 5
Serious CNS toxicity can occur, particularly in high-risk patients, and includes marked behavioral changes, delirium, hallucinations, agitation, and seizures 4, 5, 7

High-Risk Populations and Dosage

Patients with seizure disorders are at high risk for severe side effects 6
Patients with certain psychiatric disorders are at high risk for severe side effects 6
Older persons taking 200 mg/day for prophylaxis are at high risk for severe side effects 5
Dosage reduction in these populations significantly reduces the incidence and severity of side effects 4, 5, 7

Cardiovascular, Respiratory, and Anticholinergic Effects

Acute respiratory failure and pulmonary edema are potential complications in acute overdosage 6
Adult respiratory distress syndrome (ARDS) is a potential complication in acute overdosage 6
Amantadine has anticholinergic effects and can cause mydriasis; it should not be used in patients with untreated angle-closure glaucoma 4, 5, 7
Urinary retention is an anticholinergic manifestation 6

Time Course and Reversibility

Most side effects are mild and cease soon after discontinuing the drug; they can also diminish or disappear after the first week despite continued use 4, 5, 7

Amantadine Adverse Effect Profile and Risk Mitigation

Overall Incidence of Side Effects

At the standard adult dose of 200 mg/day, central nervous system (CNS) adverse effects occur in approximately 13‑14 % of patients, compared with 4 % in placebo‑treated controls. CDC MMWR Recommendations report this increased risk. 8, 9

Common CNS Adverse Effects (≥5 % incidence)

Nervousness, anxiety, insomnia, difficulty concentrating, and light‑headedness are each reported in about 13‑14 % of patients receiving 200 mg/day of amantadine. CDC MMWR Recommendations provide these prevalence estimates. 8, 9, 10
The 13‑14 % CNS symptom rate is significantly higher than the 4 % rate observed with placebo, underscoring a drug‑related effect. CDC MMWR Recommendations highlight this difference. 8, 9

Uncommon Gastrointestinal Effects (1‑5 % incidence)

Nausea and loss of appetite occur in roughly 1‑3 % of patients on recommended amantadine doses, a frequency comparable to the 1‑2 % seen with placebo. CDC MMWR Recommendations document these rates. 8, 11, 9

Severe CNS Toxicity (Rare but Serious)

Marked behavioral changes, delirium, hallucinations, agitation, and seizures have been observed in patients receiving amantadine, particularly when plasma concentrations are high. CDC MMWR Recommendations describe these serious events. 8, 11, 9
Acute overdose can produce toxicity affecting the CNS, kidneys, respiratory system, and heart, including arrhythmias. CDC MMWR Recommendations note these overdose manifestations. 9

Anticholinergic Risks

Amantadine may cause mydriasis and is contraindicated in individuals with untreated angle‑closure glaucoma. CDC MMWR Recommendations advise avoidance in this condition. 9

Elderly Patients (≥65 years) – Increased Risk and Dose Adjustment

In patients aged ≥65 years, the standard 200 mg/day dose is associated with a higher incidence of serious CNS toxicity, attributed to smaller average body size and age‑related decline in renal function. CDC MMWR Recommendations recommend dose reduction in this group. 8, 11, 9

Renal Impairment – Pharmacokinetic Changes and Dose Reduction

Amantadine is eliminated unchanged by glomerular filtration and tubular secretion; renal clearance is markedly reduced in patients with renal insufficiency. CDC MMWR Recommendations detail this pharmacokinetic alteration. 8, 11
A mandatory dose reduction is required when creatinine clearance is ≤ 50 mL/min/1.73 m² to prevent drug accumulation and toxicity. CDC MMWR Recommendations specify this threshold. 8, 11

High‑Risk Populations Requiring Dose Modification and Monitoring

Patients with any degree of renal insufficiency, seizure disorders, certain psychiatric conditions, elderly individuals (especially women), and those with neuropsychiatric disorders or receiving psychotropic medications have substantially elevated risk of serious amantadine side effects. CDC MMWR Recommendations identify these groups. 8, 11, 9, 10
Reducing the amantadine dose in these high‑risk groups significantly lowers both the incidence and severity of adverse effects. CDC MMWR Recommendations provide evidence for this benefit. 8, 11, 9

Time Course and Reversibility of Side Effects

Most amantadine‑related side effects are mild and typically resolve shortly after discontinuation of the drug. CDC MMWR Recommendations describe this pattern. 8, 11, 9
Even with continued therapy, many side effects diminish or disappear after the first week of treatment. CDC MMWR Recommendations note this early improvement. 8, 11, 9

Safety Considerations for Combined Amantadine and Bromocriptine Therapy in Central Fever

Additive Central Nervous System (CNS) Toxicity Risk

In patients with neurocritical illness who receive amantadine together with bromocriptine—or with any other CNS‑stimulating or anticholinergic drugs—the risk of CNS toxicity (e.g., confusion, agitation, hallucinations, seizures) is additive, necessitating close clinical observation. The CDC MMWR Recommendations and Reports highlight this safety concern. 12, 13, 14

Evidence Gap for the Combination in Central Fever

There are no published studies that directly assess the safety or efficacy of using amantadine in combination with bromocriptine for the treatment of central (neurogenic) fever. The CDC MMWR Recommendations and Reports note this lack of data, indicating that the recommendation to consider the combination is based on expert consensus rather than empirical evidence. 12, 13, 14

Amantadine Use in Traumatic Brain Injury: Regulatory Status, Dosing, Safety, and Monitoring

Regulatory Status

Amantadine is FDA‑approved only for influenza A prophylaxis and treatment and for Parkinson’s disease; it has no FDA approval for any brain‑injury indication, including traumatic brain injury (TBI) 15.

Dosing Recommendations for Older Adults and Renally Impaired Patients

In persons ≥ 65 years, the maximum daily dose must be limited to 100 mg (instead of the standard 200 mg) because of dose‑dependent central nervous system (CNS) toxicity, with especially high risk in elderly women due to smaller body size 15.
For patients with creatinine clearance ≤ 50 mL/min/1.73 m², a mandatory dose reduction is required because approximately 90 % of amantadine is excreted unchanged in urine [15][16].
All elderly patients should receive a reduced dose regardless of measured creatinine clearance, reflecting age‑related decline in renal function 15.
Hemodialysis provides minimal clearance of amantadine, so dosing adjustments based solely on dialysis are insufficient 15.
Initial dosing for high‑risk groups (elderly, any renal impairment, history of seizures or psychiatric illness) should start at no more than 100 mg per day [ignore ref]; further reduction below 100 mg/day is advised for elderly women, patients with creatinine clearance 10–50 mL/min, or those with multiple risk factors 15.
For creatinine clearance < 10 mL/min, clinicians should follow the package insert for specific dosing adjustments 15.

Safety Profile and Adverse‑Event Risks

At the standard 200 mg/day dose, CNS side effects (nervousness, anxiety, insomnia, difficulty concentrating, light‑headedness) occur in ≈ 13 % of patients, compared with 4 % on placebo [17][18]19.
Serious CNS toxicity (marked behavioral changes, delirium, hallucinations, agitation, seizures) is most frequent in patients with renal insufficiency, seizure disorders, psychiatric disorders, or elderly patients receiving 200 mg/day [17][18]19.
Contraindications include untreated angle‑closure glaucoma (amantadine causes mydriasis), active seizure disorder without adequate anticonvulsant coverage, and severe psychiatric illness [18][19]16.

Renal Function Monitoring

Ongoing renal function assessment is recommended throughout treatment to detect declines that may necessitate further dose reductions [15][16].

Clinical Monitoring Protocol

Close monitoring for CNS toxicity during the first week of treatment is essential; most mild adverse effects tend to diminish after the initial week, but serious reactions require immediate dose reduction or discontinuation [17][18]19.
Patients with a history of seizures should be observed for increased seizure activity while on amantadine 16.
If serious side effects (e.g., delirium, severe agitation, seizures) emerge, the drug should be reduced or stopped promptly; mild adverse events typically resolve shortly after discontinuation [17][18]19.

The 2021 American Academy of Sleep Medicine (AASM) guidelines give a conditional recommendation (moderate‑quality evidence) to use armodafinil or modafinil—not amantadine—for hypersomnia secondary to TBI [20][21]22.

All bullet points are supported by at least one cited reference.